Delta-8-THC: Scientists explain the cannabis industry’s “latest hype”

Article excerpt:

Peter Grinspoon is a primary care physician at Harvard Medical School. He’s also on the board of the advocacy group, Doctors for Cannabis Regulation. He tells Inverse that Delta-8-THC does have “vast” potential, as do many of the less-famous cannabinoids.

“I’m really excited to see what we come up with when we start breeding up, in evaluating all these different cannabinoids,” he tells Inverse. “I think Delta-8-THC is a perfect example.”

There isn’t much research directly on Delta-8-THC. Some of what we know about it comes from a 1990s study on children undergoing chemotherapy; it showed that the derivative prevented the vomiting associated with the treatment. Side effects like irritability and “slight euphoria” were only seen in two children. Though the authors noted that in children “euphoria” is hard to quantify.

Based on this early study. anti-nausea application is one potential avenue for exploration Grinspoon mentions. He adds that, based on patient experiences, this derivative “seems to be sort of more energetic and less sedating,” also has potential as an appetite suppressant.

Read the full article at Inverse

Posted in DFCR, In the Media.